{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:31:25Z","timestamp":1786735885077,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijo.ijo_342_18","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T03:12:16Z","timestamp":1534734736000},"page":"1291","source":"Crossref","is-referenced-by-count":10,"title":["Baseline morphological characteristics as predictors of final visual acuity in patients with branch retinal vein occlusions: MARVEL report no. 3"],"prefix":"10.4103","volume":"66","author":[{"given":"MichaelW","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RajeevReddy","family":"Pappuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraprasad","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadra","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MHasnat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.239351-1","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: The beaver dam eye study","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key-10.4103\/0301-4738.239351-2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in australia.The blue mountains eye study","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/0301-4738.239351-3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.239351-4","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.239351-5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: The 24-week results of the VIBRANT study","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.239351-6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","article-title":"A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no.1","author":"Narayanan","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.239351-7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/OPTH.S104459","article-title":"Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no.2","author":"Narayanan","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"key-10.4103\/0301-4738.239351-8","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.e35.","DOI":"10.1016\/j.ophtha.2010.02.031"},{"key":"key-10.4103\/0301-4738.239351-9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000327391","article-title":"Management of retinal vein occlusion \u2013 Consensus document","author":"Coscas","year":"2011","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.239351-10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ajpath.2011.04.018","article-title":"Microglia\/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: Role of PKC\u03b6 in the goto Kakizaki rat model","author":"Omri","year":"2011","journal-title":"Am J Pathol"},{"key":"key-10.4103\/0301-4738.239351-11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/IAE.0b013e318217ffc7","article-title":"Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion","author":"Ogino","year":"2012","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.239351-12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","article-title":"Optical coherence tomographic hyperreflective foci: A morphologic sign of lipid extravasation in diabetic macular edema","author":"Bolz","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.239351-13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","article-title":"Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: Analysis of protocol I data","author":"Gonzalez","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.239351-14","first-page":"972","article-title":"A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3","author":"Rajendram","year":"2012","journal-title":"Arch Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:41Z","timestamp":1786732481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_342_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"alternative-id":["239351"],"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_342_18","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}